Fresh analysis suggests that people who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop conventional lifestyle regimens.
Published data in a prominent medical journal points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users using such treatments must be cognizant of the risk of rapid rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass within about a year and a half.
Comparing Approaches
The analysis, which examined dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through lifestyle changes alone typically see a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists believe the mode of action of the injections explains the heightened regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations several times higher than normal may cause the system to produce less of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in appetite is uncontrolled, making overeating a significant risk."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," similar to managing conditions like diabetes.
Patient Testimonies
People who have discontinued the medication describe a sudden return of appetite.
"It felt as if something activating and you're instantly starving," said a patient.
This difficulty is worsened if patients have not developed sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Figures show that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and maintained weight loss hinges on ongoing lifestyle management.
